However, post hoc analyses conducted in a randomized controlled trial of lifestyle modifications in NAFLD populations have shown that variants in PNPLA3 were associated with better improvements in weight loss, better impacts on dyslipidemia, and greater reductions in intrahepatic fat, as evaluated by proton magnetic resonance spectroscopy [21]. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.